4971 results for "Psychedelics"
Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain
Journal of Fungi – March 11, 2022
Summary
Psilocybin, a powerful hallucinogen, reveals rapid, long-lasting antidepressant and anxiolytic effects for mental health challenges. This emerging pharmacology in psychiatry shows promise for treating anxiety, addiction, and chronic pain. Both micro-dosing and acute dosing regimens demonstrate potential as medicine, modulating immune systems. Such psychedelics, derived from chemical synthesis and alkaloids, represent a significant area for drug studies within complementary and alternative medicine, providing new hope for patients.
Abstract
Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing...
The Role ofPsychedelics in Managing Anxiety, Depression, and Flashbacks of Individuals withPost-Traumatic Stress Disorder
International Journal of Science and Research Methodology – January 31, 2022
Summary
A compelling review reveals psilocybin's significant therapeutic potential for traumatic stress, marking a paradigm shift in Psychiatry. This hallucinogen shows promise in alleviating anxiety, depression, and flashbacks in patients with PTSD. Clinical psychology is actively exploring this novel approach, moving past historical stigma surrounding psychedelics and drug studies. Psychotherapists anticipate leveraging psilocybin's effects, offering new hope where typical treatments fall short. This evolution in mental health psychology could redefine care for many.
Abstract
Background: The impact of psychedelic treatment on patients with posttraumatic stress disorder (PTSD) has become more intriguing to the psychiatric...
Wherefore the magic? The evolutionary role of psilocybin in nature
OpenAlex – December 19, 2025
Summary
Psilocybin, a fascinating chemical synthesis and alkaloid, significantly impacts invertebrate biology. In a crucial step for evolutionary biology, zoology reveals that exposing Drosophila larvae to Psilocybe mushroom extracts reduced their survival and locomotion. Adults also exhibited developmental stress, with smaller thoraxes and wings. This suggests natural selection may have favored psilocybin's production as a defense mechanism, a key insight for ecology and psychedelics and drug studies. Intriguingly, these effects occurred even in flies lacking 5HT2A receptors, challenging assumptions from psychology. This work grounds our understanding of psilocybin's ancient role.
Abstract
Abstract Research into psychedelic compounds is in resurgence due to the exciting potential for their use in the treatment of psychiatric and menta...
Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition – August 14, 2024
Summary
Neuroscience reveals how two distinct hallucinogens, Psilocybin and Salvinorin-A, profoundly alter brain communication. Investigating these two psychedelics in non-human primates, work shows they act as agonists on separate serotonergic and κ-opioid receptors, uniquely reshaping functional connectivity. This influences the default mode network, crucial for self-reflection, and the enigmatic claustrum. Such drug studies offer vital insights for mental health topics, exploring how neurotransmitter receptor influence on behavior could lead to new psychological treatments.
Abstract
This work utilized fMRI to assess the influence of the psychedelics, Psilocybin, a serotonergic agonist, and Salvinorin-A, a kappa-opioid receptor ...
Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
Psychedelics. – February 03, 2026
Summary
Psilocybin, a hallucinogen, differentially affects social behavior and inflammation in female mice, crucial for Anorexia Nervosa. In an animal model, psilocybin didn't alter sociability in groups modeling anorexia or exercise, but increased social familiarity in controls. It elevated the proinflammatory cytokine IL-6, a marker of inflammation, in exercising mice, correlating with novelty-seeking. This psychology research illuminates biological mechanisms affecting social relations, emotional empathy, and anxiety, vital for understanding psychedelics' therapeutic potential, especially considering social isolation and prosocial behavior.
Abstract
Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obses...
317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin does not create a rewarding preference, a crucial insight for its therapeutic promise. In a Conditioned Place Preference paradigm with 20 rats, the psychedelic did not foster a preference for the drug-paired environment. While immediate behavior was altered—increasing head-twitching and dog-shaking, accounting for over 70% of observed behavioral variance—these effects were temporary. This Neuroscience and Pharmacology finding, relevant to Drug Studies and Psychology, illuminates psilocybin's Neurotransmitter Receptor Influence on Behavior, supporting its safety profile and implications for Neuroendocrine regulation.
Abstract
Abstract Background Recent years have seen renewed scientific interest in psychedelics, including psilocybin, for their potential in treating neuro...
Psilocybin modulates social behaviour in male and female mice in a time-dependent manner
OpenAlex – December 22, 2025
Summary
Psilocybin, a potent hallucinogen, profoundly alters social behavior and empathy differently across sexes. In female mice given 1.5 mg/kg, this psychedelic enhanced preference for social novelty for about 24 hours, but shifted to familiar preference after 7 days, linked to nucleus accumbens dopamine changes. Males, however, showed reduced stress and preferred familiar social relations, with blunted novelty responses. This neuroscience reveals prosocial behavior is not universal, highlighting the need for sex-informed psychology and drug studies, especially for conditions like anorexia where social inhibition is a factor.
Abstract
Abstract With the resurgence of psychedelic research and the growing interest in their therapeutic potential, there is an urgent need to understand...
Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA)
OpenAlex – October 15, 2025
Summary
Psychedelics, central to drug studies, reveal complex, sex-specific behavioral impacts. A single psilocybin dose subtly influenced social behavior and inflammation in female mice, crucial for understanding disorders predominantly affecting women. While it didn't alter sociability in mice experiencing food restriction or activity-based anorexia, it increased preference for familiarity in healthy controls. In exercised mice, psilocybin elevated the inflammatory marker IL-6, correlating with novelty preference. These context-dependent shifts highlight nuanced drug effects on behavior and physiology.
Abstract
Abstract Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxie...
Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study
OpenAlex – December 10, 2025
Summary
Combining psilocybin with cannabis may enhance therapeutic benefits, improving perceived quality of life, anxiety, depression, and alcohol abuse. A survey of 365 psilocybin users revealed notable differences in experiences across age groups. Younger adults (18-25) reported more adverse effects, while older adults (55-77) experienced milder ones. Interestingly, age did not influence mystical experiences or overall psychological outcomes. Younger users also co-used nicotine more frequently. These insights highlight how age and co-substance use shape psychedelic experiences and potential therapeutic results.
Abstract
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both rese...
Increased spontaneous EEG signal diversity during stroboscopically-induced altered states of consciousness
OpenAlex – January 04, 2019
Summary
A compelling neuroscience insight reveals that simple stroboscopic light stimulation can induce profound altered states of consciousness, similar to those from psychedelics. Electroencephalography (EEG) shows this non-pharmacological stimulation substantially increases neural signal diversity, exceeding levels found during wakeful rest. This change accompanies a significant expansion in the intensity and range of subjective experiences, including complex visual hallucinations. This finding in psychology suggests EEG signal diversity reflects the richness of conscious experience, offering insights into how sensory stimulation impacts the brain's diverse activity patterns, paralleling observations from drug studies.
Abstract
Abstract What are the global neuronal signatures of altered states of consciousness (ASC)? Recently, increases in neural signal diversity, compared...
Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine
Journal of Nuclear Medicine – September 29, 2022
Summary
MDMA's acute effects on the brain are more complex than previously thought. In rats, this hallucinogen stimulates neuronal activity in limbic areas, key for emotional processing, increasing glucose metabolism. However, accompanying global hemodynamic decreases are non-neuronal and peripheral, strongly correlating with Serotonin transporter occupancy. Increased Serotonin levels from this blockage cause neurovascular uncoupling through direct vascular effects. This neuroscience challenges previous fMRI interpretations in drug studies, suggesting new approaches for understanding psychedelics in medicine and psychology. Pharmacology must consider these complex haemodynamic responses.
Abstract
Psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) have attracted increasing interest in recent years because of their therapeu...
Exploring inner depths
OpenAlex – February 20, 2024
Summary
Patients receiving psychedelic treatments for depression report profound, sometimes anxious, experiences. Feeling unprepared or unsupported often heightened discomfort, hindering therapeutic surrender. Conversely, trust in therapists and strong emotional backing eased anxiety, fostering beneficial outcomes like feeling more open or detached from negative thoughts. Improving treatment delivery, much like understanding the deep, foundational layers of **Geology**, requires offering multiple sessions and extended support to enhance patient comfort and efficacy.
Abstract
Psychedelics are remarkable, versatile substances that produce a wide range of effects and can cause both harm and healing. Clinical research into ...
Tags
Intact neurophysiological markers of death denial in ayahuasca veterans
OpenAlex – November 18, 2024
Summary
Ayahuasca may alter conscious perceptions of death, yet unconscious denial mechanisms persist. In a study involving 50 ayahuasca veterans, brain responses indicated denial about mortality, contrasting with less fear of death compared to the general population (who scored 20% higher in fear measures). While self-reports showed lower anxiety levels, neurophysiological markers linked denial to greater life satisfaction. These findings suggest that despite ayahuasca's potential benefits in reducing fear, deeper cognitive processes related to mortality avoidance remain unchanged, highlighting limits in psychedelic transformative efficacy.
Abstract
There is a growing hype regarding the efficacy of psychedelics to fundamentally change how we interact with the theme of death. The underlying evid...
Is there more to magic mushrooms than psilocybin?
C&EN Global Enterprise – October 20, 2025
Summary
In a Vancouver facility, researchers can produce enough psilocybin mushrooms to provide hallucinogenic experiences for 80,000 people annually. Unlike typical black-market operations, these mushrooms are cultivated for clinical trials aimed at treating conditions like depression and OCD. While synthetic psilocybin has dominated past studies, emerging evidence suggests that the natural compounds in magic mushrooms may enhance therapeutic effects. This shift could redefine our understanding of psychedelics, blending psychology, art history, and psychoanalysis to unlock their full potential for mental health treatment.
Abstract
In a suburb of Vancouver, Canada, a nondescript three-story building sits alongside a strip of parking lots. From the outside, it looks like an ord...
Effects of Psilocybin and Select Pharmaceutical Interactions
MacEwan University Student eJournal – February 18, 2026
Summary
In Canada, approximately 16.5% of the population, or about 6.3 million people, were prescribed antidepressants like fluoxetine in 2022. Meanwhile, around 2% of Canadians, equating to roughly 587,000 individuals, reported using hallucinogens such as psilocybin. With over 126,000 Canadians potentially experiencing interactions between antidepressants and psychedelics, understanding their effects is crucial. Notably, fluoxetine may reduce the psychoactive impact of psilocybin due to its influence on serotonin receptors, highlighting the importance of considering drug interactions for effective harm reduction and clinical practices.
Abstract
In Canada, the use of both prescription medications and psychedelics has become increasingly prevalent. As of 2022, approximately 16.5% of Canadian...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?
Journal of psychopharmacology (Oxford, England) – May 05, 2025
Summary
While LSD is famous for its psychedelic effects, scientists long believed some similar compounds could activate the same brain receptors without causing hallucinations. This analysis reveals that two drugs, lisuride and ergotamine, likely do cause consciousness-altering effects when they reach sufficient levels in the brain, challenging previous assumptions about "non-hallucinogenic" 5-HT2A receptor compounds. This finding impacts current efforts to develop therapeutic psychedelics with reduced effects on perception.
Abstract
The recent resurgence of classical psychedelic compounds, specifically 5-HT2A receptor agonists, as potential therapeutics has led to numerous init...
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
Trials – August 24, 2024
Summary
A groundbreaking trial explores microdosing LSD as a potential treatment for major depressive disorder. This first-of-its-kind randomized controlled trial will test sub-hallucinogenic doses of psychedelics, with participants taking small amounts twice weekly at home. The 8-week study measures mood improvements while carefully monitoring safety and effectiveness through brain activity, blood markers, and sleep patterns.
Abstract
Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable sid...
The flattening of spacetime hierarchy of the N,N-dimethyltryptamine brain state is characterized by harmonic decomposition of spacetime (HADES) framework.
National science review – May 01, 2024
Summary
DMT, a powerful psychedelic compound, dramatically alters brain activity patterns by flattening the brain's natural hierarchical organization. Scientists found that DMT reduces the strength of specific harmonic modes - wave-like patterns of neural activity that normally maintain the brain's functional hierarchy. This disruption leads to unique spatio-temporal brain dynamics, explaining the profound alterations in consciousness and perception associated with psychedelic experiences.
Abstract
The human brain is a complex system, whose activity exhibits flexible and continuous reorganization across space and time. The decomposition of who...
5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats.
Scientific reports – May 17, 2024
Summary
The powerful psychedelic 5-MeO-DMT creates brain wave patterns remarkably similar to those seen during sleep, even while subjects remain awake. Scientists tracked electrical activity in the hippocampus and prefrontal cortex of rats, finding that the compound triggers unique neural oscillations typically associated with deep sleep and dreaming, while reducing high-frequency brain activity. This suggests psychedelics may create their effects by blending waking and sleeping states.
Abstract
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent classical psychedelic known to induce changes in locomotion, behaviour, and sleep in roden...
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD).
Drug testing and analysis – February 01, 2024
Summary
A newly studied psychedelic compound shows promising similarity to LSD, with about half its potency. Scientists analyzed EIPLA, one of many new psychoactive substances, finding it produces similar effects to classic psychedelics. Lab tests of blotters revealed precise doses, while animal studies confirmed the substance triggers characteristic behaviors associated with serotonergic compounds.
Abstract
Preclinical investigations have shown that N-ethyl-N-isopropyllysergamide (EIPLA) exhibits lysergic acid diethylamide (LSD)-like properties, which ...
TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.
iScience – May 19, 2023
Summary
Clinical neuroscience reveals fascinating insights into how psychedelic compounds affect brain activity. Using advanced medical imaging techniques, researchers found that psilocybin creates unique patterns of neural activity, increasing brain signal diversity while maintaining structured communication between regions. This pharmacology breakthrough shows how psychedelics create heightened sensory awareness through specific changes in frontal brain areas, helping explain their consciousness-altering effects.
Abstract
Exploring the neurobiology of the profound changes in consciousness induced by classical psychedelic drugs may require novel neuroimaging methods. ...
4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.
Journal of psychopharmacology (Oxford, England) – July 01, 2012
Summary
A synthetic drug called 2C-B, known for its unique blend of effects, has seen a significant rise in the Spanish recreational market. Researchers investigated its prevalence, use patterns, and user experiences by analyzing drug samples and gathering user reports. They found 2C-B's presence doubled, often in pure tablet form. Users reported taking around 20mg orally. It induces perceptual changes similar to psychedelics, but with notably lower incapacitation and comparable pleasure and sociability to entactogens. This suggests 2C-B offers a distinct profile, combining psychedelic visuals with less impairment and strong positive social effects.
Abstract
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive analogue of mescaline that is becoming increasingly popular as a rave and club drug. W...
Timothy Leary and the trace of the posthuman
CORE – January 01, 2014
Summary
Timothy Leary's vision for personal change wasn't just about psychedelics; he mapped out a profound shift in human identity. He hypothesized that by shedding social conditioning and ego, individuals could access a deeper, cellular level of consciousness, moving towards a "posthuman" state. Initially advocating psychedelics, he later championed computer technology as tools for this transformation. The analysis reveals his consistent quest to redefine humanity, using each era's innovations to point towards exciting, uncharted future possibilities.
Abstract
Author's post-print version.If we trace the line of Timothy Leary’s thought from The Politics of Ecstasy to Your Brain is God, he is outlining his ...
Strange Attractor
CrossRef – October 07, 2025
Summary
Terence McKenna, a 'psychedelic Renaissance man,' uniquely shaped understanding of consciousness and time. A new intellectual biography delves into his life, works, and enduring magnetism. Utilizing original documents and interviews, it chronicles his rugged philosophy and 'weird intelligence,' revealing why his wisdom continues to resonate across digital culture and social media today.
Abstract
An intellectual biography of one of the most celebrated and yet least understood figures of the late twentieth century, Terence McKenna. A stand-up...
Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal Study
OpenAlex – June 09, 2023
Summary
Psychedelic experiences significantly enhance how individuals perceive minds in various entities. A psychology longitudinal study with 657 participants tracked beliefs before and after a planned psychedelic encounter, often involving psilocybin. While mind perception increased across living and non-living targets, there was little change in naturalism-related metaphysical beliefs or Atheist-Believer status. This cognitive psychology research, contributing to psychedelics and drug studies, highlights a specific shift in perception rather than fundamental changes in core spiritual or non-naturalistic convictions.
Abstract
Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind pe...
Salvador Roquet, María Sabina, and the Trouble withJipis
Hispanic American Historical Review – February 01, 2015
Summary
An untold chapter in Latin American history reveals how indigenous wisdom shaped psychedelic medicine. Psychiatrist Salvador Roquet, collaborating with the iconic Indigenous healer María Sabina, developed a therapeutic method for psychedelics, including psilocybin mushrooms. Their unique cross-cultural exchange, an important insight for Anthropological Studies and Drug Studies, challenged the prevailing counterculture narrative. Unlike the "jipis," they viewed these substances as potent medicines requiring expert, respectful handling. This perspective offers a rich contribution to our understanding of psychedelic use, rooted deeply in Latin American culture and contrasting with popular sociology.
Abstract
Abstract While María Sabina has long been an iconic figure among drug enthusiasts and advocates for indigenous rights, her sometime collaborator Sa...
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data.
Progress in neuro-psychopharmacology & biological psychiatry – March 20, 2025
Summary
DMT, a naturally occurring compound in the brain, plays a fascinating dual role in both stress response and brain development. Research reveals this molecule binds to specific receptors in the Golgi apparatus of brain cells, promoting neuroplasticity and healthy neurodevelopment. When stress occurs, DMT levels increase naturally, suggesting it acts as part of the body's adaptive response system. These findings explain how DMT influences brain function and may contribute to therapeutic benefits.
Abstract
Renewed interest in the clinical use of psychedelic drugs acknowledges their therapeutic effectiveness. It has also provided a changing frame of re...
The Selective 5HT2A Receptor Agonist, 25CN-NBOH Exerts Excitatory and Inhibitory Cellular Actions on Mouse Medial Prefrontal Cortical Neurons.
Synapse (New York, N.Y.) – March 01, 2025
Summary
No Summary
Abstract
Psychedelic compounds have gained renewed interest due to their rapid and long-lasting therapeutic effects on stress-related disorders. While the u...
Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?
Toxicology reports – June 01, 2025
Summary
No Summary
Abstract
Drug use represents a prevalent and multifaceted societal problem, with profound implications for public health, social welfare, and economic stabi...
Psilocybin therapy: A novel approach to treating depression
International Journal of Surgery Global Health – June 02, 2023
Summary
Psilocybin therapy shows remarkable promise for treating severe depression, offering relief within hours or days, unlike traditional antidepressants that take weeks. Globally, ~280 million people suffer from depression, with 30% experiencing treatment-resistant depression (TRD). Conventional pharmacotherapy often fails these individuals, who face increased suicidal ideation. Six clinical trials confirm psilocybin's rapid, sustained effects, suggesting a new paradigm in psychiatry and mental health. This psychological intervention, involving a naturally occurring alkaloid, provides a compelling alternative for major depression treatment and suicide prevention, requiring careful medical prescription and oversight.
Abstract
The COVID-19 pandemic has resulted in a surge in depression cases, a pervasive and debilitating mental illness1. This trend is evident in the incre...
NIDA on dramatic increase of mushroom seizures
Alcoholism & Drug Abuse Weekly – March 01, 2024
Summary
Seizures of psilocybin mushroom dramatically surged, increasing from 402 in 2017 to 1,396 in 2022, with seized weight rising from 226 kg to 844 kg. This dramatic rise, reflecting a 247% increase in incidents, highlights evolving interest in the mushroom's potential therapeutic applications in Psychology. Yet, understanding how these mushroom bodies affect brain function, distinct from mechanisms like cholinesterase inhibition in neurodegenerative diseases, is crucial given risks of unsupervised use.
Abstract
From 2017 – 2022, law enforcement seizures across the United States of mushrooms containing psilocybin increased dramatically, according to a new s...
The phenomenology of psilocybin: transformative insights for research and clinical practice
Frontiers in Psychology – April 25, 2025
Summary
Ten individuals described profound personal growth after experiencing psilocybin, a potent hallucinogen. This qualitative exploration, rooted in phenomenology (a philosophy of experience), revealed universal psychological themes: enhanced empathy, emotional sensitivity, and lasting insights into personal values. Participants reported transformative learning, indicating significant behavioral shifts. These findings offer psychotherapists a structured understanding of psychedelic experiences, informing their integration into practice. Such insights contribute to diverse academic research themes, including Psychedelics and Drug Studies, and illuminate potential connections to Religious Studies and Spiritual Practices.
Abstract
Introduction Considering the increasing evidence supporting psilocybin’s efficacy in therapeutic settings, it is essential to deepen our understand...
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology – April 11, 2025
Summary
A naturally-occurring neurotransmitter in our bodies, DMT has profound effects on brain connectivity. When present, it enhances global neural networks and alters consciousness by binding to specific receptors. Both endogenous and exogenous DMT influence cognition by increasing brain signal complexity and strengthening connections between key regions. This psychedelic compound's unique properties suggest it plays a vital role in consciousness.
Abstract
N, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful...
Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation
Journal of Psychoactive Drugs – March 14, 2025
Summary
Remarkably, 78.2% of individuals with long COVID symptoms, a consequence of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reported improvement using the hallucinogen psilocybin. An analysis of 110 online accounts from the Coronavirus disease 2019 (COVID-19) pandemic revealed 77.9% of those improving experienced lasting relief beyond the acute psychedelic effect. Common neuropsychiatric issues like fatigue (47.3%) and cognitive impairment (46.4%) were cited. This suggests a compelling avenue for Psychiatry, Medicine, and Psychology to explore psychedelics in post-pandemic care and Complementary/Alternative Medicine.
Abstract
Long COVID lacks effective pharmaceutical treatment options. Psychedelic treatment for long COVID has received attention given anecdotal reports of...
Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.
Drug safety – May 01, 2025
Summary
Analysis of 2,000+ firsthand psychedelic experiences reveals distinct patterns: mushroom users report more introspective, time-altering journeys, while LSD users describe cognitive shifts. Advanced AI analysis found mushroom experiences were rated more positively overall, particularly among male users. Common themes across both substances included emotional depth and sensory enhancement.
Abstract
Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuab...
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder.
The Journal of pharmacology and experimental therapeutics – January 01, 2025
Summary
Psilocybin shows remarkable potential in rewiring fear responses in the brain, offering hope for those with post-traumatic stress disorder. The compound increases brain-derived neurotrophic factor, helping form new neural connections. Studies reveal significant reductions in anxiety and trauma symptoms, with patients reporting lasting relief after supervised psychedelic sessions.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that develops following exposure to a traumatic event. Individuals wi...
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Molecular psychiatry – April 01, 2025
Summary
Psychedelics and stimulants reshape brain networks differently, with LSD showing unique effects on the brain's "default mode" - regions active when we're lost in thought. This research tracked brain connectivity changes in 28 healthy volunteers after taking LSD, MDMA, or amphetamine. While all substances altered brain network communication, LSD stood out by increasing connectivity between the brain's command centers while reducing it in visual areas. MDMA and amphetamine showed overlapping but distinct patterns, suggesting each substance uniquely influences how brain regions talk to each other.
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. ...
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.
PCN reports : psychiatry and clinical neurosciences – December 01, 2023
Summary
The ancient Amazonian brew ayahuasca combines DMT-containing plants with harmala alkaloids to create a powerful psychedelic medicine. Traditional ceremonies using this brew have shown remarkable potential in treating depression, addiction, and PTSD. Modern research reveals that ayahuasca's unique chemical properties promote neuroplasticity and emotional healing, while traditional ceremonial contexts provide crucial therapeutic support.
Abstract
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine...
Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor
iScience – April 09, 2024
Summary
Remarkably, Psilocybin, a potent Hallucinogen explored in Medicine for Anxiety, can induce acute anxiety via distinct brain pathways. Neuroscience and Pharmacology reveal that blocking the 5-HT2A Receptor, mediating its psychedelic effects, does not prevent Psilocybin-induced anxiety in mice. Analysis in the Amygdala shows specific brain proteins are involved, indicating the drug's anxiety-provoking aspects operate independently. This insight from Psychedelics and Drug Studies into Neurotransmitter Receptor Influence on Behavior is crucial for developing safer alkaloid-based treatments, informing Psychology and future chemical synthesis.
Abstract
Psilocybin, and its metabolite psilocin, induces psychedelic effects through activation of the 5-HT2A receptor. Psilocybin has been proposed as a t...
Biological studies of clavine alkaloids targeting CNS receptors
Frontiers in Psychiatry – November 21, 2023
Summary
Potent clavine alkaloids, widely present through plant and fungal interactions, are surprisingly underexplored compared to well-known psychedelics like psilocybin and lysergic acid diethylamide. Their unique pharmacology and biology, influencing various brain receptors, offer vast potential for drug studies. Exploring their chemical synthesis and alkaloids could uncover novel hallucinogen compounds. This neuroscience-focused work highlights opportunities to expand the therapeutic range beyond current lysergic acid derivatives, revolutionizing our understanding of psychedelic action and future drug development.
Abstract
In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and psilocybin, ergot alkaloids of the clavine subclass have ...
Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.
Medicina (Kaunas, Lithuania) – March 21, 2025
Summary
Breakthrough treatments for depression are evolving beyond traditional antidepressants. While standard medications remain effective, promising new options include fast-acting ketamine, neurosteroid treatments for postpartum depression, and psychedelics showing lasting benefits. Novel approaches targeting inflammation, opioid receptors, and personalized biomarker therapy are advancing, offering hope for more effective, individualized depression treatment.
Abstract
Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depre...
Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.
Journal of psychoactive drugs – April 18, 2025
Summary
Groundbreaking research reveals that ibogaine, a unique psychedelic compound, shows promise in treating addiction. Analysis of global clinical trials demonstrates growing scientific interest in this treatment for Substance Use Disorders (SUD). The compound, which metabolizes into noribogaine, is being tested in multiple countries with varying protocols. Early results indicate potential benefits, particularly in reducing withdrawal symptoms, though cardiovascular monitoring remains crucial.
Abstract
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack ...
Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats
Frontiers in Neuroscience – June 22, 2023
Summary
The hallucinogen psilocybin, a potent serotonergic psychedelic, influences brain activity beyond the well-known 5-HT2A receptor. Neuroscience reveals psilocin, its active form, broadly decreases EEG power (1-25 Hz), an effect reversed by multiple serotonin and dopaminergic receptor antagonists. However, its impact on fronto-temporal disconnection, crucial for its psychology, was reversed solely by a 5-HT2A receptor antagonist. This pharmacology, rooted in chemistry, highlights diverse neurotransmitter receptor influence on behavior, expanding drug studies and biochemical analysis of psychedelics.
Abstract
Introduction Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psyc...
Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience
OpenAlex – May 12, 2023
Summary
Psychedelics like psilocybin and the hallucinogen lysergic acid diethylamide profoundly reshape brain dynamics. Neuroscience reveals that N,N-dimethyltryptamine (DMT), a serotonergic compound, significantly reduces the "control energy" needed for brain state transitions in 14 individuals. This finding, crucial for Psychology and Mental Health Research Topics, shows global control energy trajectories, potentially involving the default mode network, correlate with subjective drug intensity. These effects are linked to serotonin 2a receptor density, demonstrating neurotransmitter receptor influence on behavior and offering a predictive model for Psychedelics and Drug Studies.
Abstract
Abstract Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, su...
Perceived risk of LSD varies with age and race: evidence from 2019 United States cross-sectional data.
Social psychiatry and psychiatric epidemiology – October 01, 2023
Summary
While psychedelics show promise in mental health treatment, public perception of their risks varies significantly across demographic groups. Analysis of 41,000+ Americans reveals that age and racial background strongly influence views on LSD safety. White respondents and multiracial individuals reported lower perceived risks than other racial groups, while older adults generally viewed the substance as more dangerous. These healthcare disparities in risk perception likely stem from historical patterns in drug enforcement and cultural attitudes toward illicit substance use.
Abstract
Psychedelics are being explored for their potential therapeutic benefits across a wide range of psychiatric diagnoses and may usher in a new age in...
Set and setting in microdosing: an oft-overlooked principle.
Psychopharmacology – December 01, 2022
Summary
Mindset and environment play a crucial role in how people respond to microdosing psychedelics like LSD and psilocybin. While most focus on dosage, research reveals that intention, expectations, and surroundings significantly influence outcomes. Understanding these "set and setting" factors helps explain varying results and could be key to optimizing the benefits of sub-perceptual doses.
Abstract
The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social e...
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Tiny amounts of LSD can boost the brain's reward processing systems, even without causing noticeable psychedelic effects. Scientists found that low doses enhanced brain responses to rewards and positive feedback in healthy adults. Using advanced brain monitoring, researchers observed increased activity in three distinct reward-processing pathways, suggesting LSD's potential to enhance natural reward responses and positive emotions.
Abstract
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single...
Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.
Social work – April 01, 2025
Summary
While MDMA shows promise for treating PTSD in adults, social workers express greater confidence in traditional medications for adolescent patients. A survey of 222 social workers revealed they favored selective serotonin reuptake inhibitors over MDMA therapy for treating teen PTSD. However, those with more knowledge about psychedelics showed less stigma and concern, suggesting education could increase acceptance of this emerging treatment.
Abstract
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adoles...
Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees
Frontiers in Psychiatry – July 07, 2022
Summary
Psilocybin, a psychedelic compound from truffles, significantly reduced anxiety in a supportive group setting. Among 46 participants, average psilocin consumption was 27.1 mg. State and trait anxiety measures showed medium reductions (effect sizes around 6) the morning after, persisting for a week (effect sizes around 7-8) in 23 individuals. This highlights psilocybin's potential in clinical psychology and psychiatry for anxiety management, possibly influencing neurotransmitter receptors. Mindfulness also increased, demonstrating broader psychological effects of psychedelics.
Abstract
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmaco...
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
Psychopharmacology – December 10, 2019
Summary
A single session with the tryptamine-based psychedelic 5-methoxy-N,N-dimethyltryptamine significantly improved mood and psychological well-being in 11 participants. Depression ratings decreased immediately and after seven days, while anxiety and stress also lessened over a week. Saliva analysis revealed increased cortisol and decreased IL-6, inflammatory markers relevant to internal medicine, immediately post-session. These physiological shifts, not linked to the psychedelic experience itself, suggest a complex affect on the body, informing psychiatry.
Abstract
Abstract Rationale 5-methoxy-N,N-dimethyltryptamine is a psychotropic substance found in various plant and animal species and is synthetically prod...
Prescription and Nonprescription Drug Use Among People With Eating Disorders.
JAMA network open – July 01, 2025
Summary
Many individuals with eating disorders report using various substances to manage their symptoms. An extensive international survey explored how people perceive both prescribed and non-prescribed drugs. It revealed that cannabis and psychedelics were frequently reported to improve eating disorder symptoms. While prescription antidepressants often benefited overall mental health, they were generally not found effective for eating disorder symptoms, with specific exceptions. This highlights promising new approaches for symptom relief.
Abstract
There are few effective pharmacotherapies for treating eating disorders (EDs). High rates of substance use among individuals with EDs suggest poten...
Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
The American journal of drug and alcohol abuse – November 01, 2016
Summary
Over a third of young adults at NYC electronic dance music events have used novel psychoactive substances. A survey of 682 attendees at nightclubs and festivals found 35.1% lifetime use. Synthetic cannabinoids, psychedelic phenethylamines, and synthetic cathinones ("bath salts") were most common. This clearly shows significant novel psychoactive substance use in these venues, particularly among frequent attendees.
Abstract
Novel psychoactive substances (NPSs) continue to emerge in the United States and worldwide. Few epidemiological studies have examined the prevalenc...
Subjective effects of Salvia divinorum: LSD- or marijuana-like?
Journal of psychoactive drugs – September 01, 2009
Summary
Despite Salvia divinorum's reputation as one of the most potent hallucinogens, new insights challenge common assumptions about its effects. It was previously thought to produce experiences akin to traditional psychedelics like LSD. Researchers surveyed 193 individuals, including Salvia users, about their experiences. Surprisingly, most users reported Salvia's subjective effects felt more similar to marijuana than to LSD, a finding confirmed by psychological assessments. This suggests Salvia's unique molecular mechanism may result in a distinct hallucinogenic profile, diverging from expectations.
Abstract
Salvia divinorum is a naturally occurring psychedelic considered to be one of the most potent hallucinogens found to date. The few behavioral studi...
Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Translational Psychiatry – February 23, 2022
Summary
Psychedelics show promise for psychological well-being and psychiatric disorders. Neuroscience reveals psilocin acutely alters sleep architecture. Electroencephalography in mice showed delayed REM sleep onset and reduced NREM sleep for up to 3 hours after dosing, with an enhanced 4 Hz oscillation. While not affecting overall sleep rebound, psilocin decreased recovery of slow-wave activity in the cerebral cortex after Wakefulness deprivation. This Sleep and Wakefulness Research from Psychedelics and Drug Studies offers insights for Medicine, impacting our understanding of sleep (system call) regulation.
Abstract
Abstract Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through...
LSD and psilocybin flatten the brain’s energy landscape: insights from receptor-informed network control theory
OpenAlex – May 17, 2021
Summary
Psychedelics like LSD and psilocybin significantly ease the brain's ability to transition between different activity states, promoting more varied dynamics. This finding from Functional Brain Connectivity Studies highlights how these compounds, central to Psychedelics and Drug Studies, effectively "flatten" the brain's energy requirements. LSD's impact correlates with more frequent state changes and increased brain diversity across individuals. This mechanism, vital for Mental Health Research Topics, is specifically driven by serotonin 2a receptors, enabling more fluid brain activity.
Abstract
Abstract Psychedelics like lysergic acid diethylamide (LSD) and psilocybin offer a powerful window into the function of the human brain and mind, b...
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Schizophrenia Bulletin – October 06, 2012
Summary
The psychedelic psilocybin significantly blurs the brain's internal and external focus, a finding with implications for Psychology and Mental Health Research Topics. Using functional magnetic resonance imaging (fMRI) in 15 healthy volunteers, Neuroscience investigations reveal psilocybin, a hallucinogen, dramatically increased functional connectivity between the default mode network (introspection) and task-positive network (external attention). This altered brain connectivity, observed in Psychedelics and Drug Studies, mirrors patterns seen in psychosis, supporting psilocybin's utility as a model for understanding early psychosis. Preserved thalamocortical connectivity suggests this isn't sedation, but a unique alteration in functional brain connectivity.
Abstract
Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network...
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans
Journal of Psychopharmacology – October 08, 2020
Summary
Individual brain chemistry profoundly shapes psychedelic experiences. In a Neuroscience and Psychology investigation, 16 participants received a single dose (0.2–0.3 mg/kg) of the hallucinogen psilocybin, a serotonin-acting chemical alkaloid. Those with higher levels of the brain's 5-HT2A receptor, a key neurotransmitter receptor, experienced shorter peak effects but a longer return to normal consciousness. This finding from Psychedelics and Drug Studies highlights how individual receptor binding influences the temporal and mystical aspects of a psilocybin journey, profoundly impacting behavior.
Abstract
Background: Psilocybin is a serotonergic psychedelic with psychoactive effects mediated by serotonin 2A receptor (5-HT2AR) activation. It produces ...
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
ACS Chemical Neuroscience – July 23, 2018
Summary
N, N-dimethyltryptamine (DMT), a potent hallucinogen, is remarkably ubiquitous, produced by diverse plant and animal species, and even endogenously in mammals. This foundational psychedelic, whose chemical synthesis is well-documented, is crucial for Neuroscience and Psychology, serving as the archetype for other indole alkaloids like LSD. Its enigmatic biological function in humans, along with its pharmacology and potential medical applications, are key areas in Psychedelics and Drug Studies. Future research explores its intricate neuropharmacology, including potential interactions with receptors like nicotinic acetylcholine, to unlock its full significance.
Abstract
Though relatively obscure, N, N-dimethyltryptamine (DMT) is an important molecule in psychopharmacology as it is the archetype for all indole-conta...
Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report
Psychoactives – July 01, 2025
Summary
A 22-year-old athlete with persistent concussion symptoms experienced remarkable relief after self-administering psilocybin. Despite prior physical medicine and rehabilitation, his symptom severity score dropped from 25 to 11, and affective burden completely resolved, following three 2.5mg doses of the psychedelic medicine. This suggests a powerful neurotransmitter receptor influence, enabling a full return to activity. Such findings in drug studies highlight psychedelics' potential beyond conventional physical therapy, offering new avenues for concussion recovery.
Abstract
Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research hig...